"Novartis" Jordan launches first of its kind drug in the world to manage Systolic Heart Failure
Novartis announced the launching of its new drug; LCZ696 (sacubitril/valsartan) in the Jordanian market, the first of its kind in the world to manage Systolic Heart failure. This has come during a special scientific meeting,
Novartis announced the launching of its new drug; LCZ696 (sacubitril/
Systolic Heart failure is life-threatening to patients and causes debilitation of the body due to the fact that the heart is unable to pump sufficient amount of blood. Among its symptoms; shortness of breath, extreme fatigue, in addition to fluid retention. These symptoms are slow in progress and exacerbate over time which may negatively impacts the quality of patients' lives.
The importance of this step comes after publication of the PARADIGM-HF data analysis, showcased during the 65th Annual Scientific Conference organized by the American Cardiovascular Faculty in Chicago. The analysis showed that (sacubitril/
The benefit of this drug is further enhanced by being the first drug that reduces the strain on the failing heart by enhancing the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-
The introduction of this drug into the Jordanian market represents a window of hope for heart failure patients who are taking higher or lower doses of beta blockers and those who are dependable on an implantable cardioverter-